Biomarker panel for detecting lung cancer
AssigneeRush University Medical Center
InventorsJeffrey A. BORGIA, Michael LIPTAY
Life of this patent
Estimating the term…
Abstract
A method and a kit for assessing risk of lung cancer versus benign disease in a subject are provided. The method includes obtaining a biological sample from the subject and determining a measurement for a panel of biomarkers in the biological sample. The panel includes at least two biomarkers selected from the group consisting of IL-6, IL-1ra, IL-10, SDF-1α+β, TNF-α, MIP-1α, sIL-2Rα, CA-125, sE-Selectin, Eotaxin, sEGFR, MMP-2, OPN, MCP-1, CRP, sICAM-1 and CYFRA 21.1. The method further includes comparing the measurement to a reference profile for the panel of biomarkers, sorting the subject into a group and determining whether the subject is at risk for lung cancer based on the group.
Claims24
A method of assessing risk of lung cancer versus benign disease in a subject, the method comprising:
- obtaining a biological sample from the subject;
- determining a measurement for a panel of biomarkers in the biological sample, the panel comprising at least two biomarkers selected from the group consisting of IL-6, IL-1ra, IL-10, SDF-1α+β, TNF-α, MIP-1α, sIL-2Rα, CA-125, sE-Selectin, Eotaxin, sEGFR, MMP-2, OPN, MCP-1, CRP, sICAM-1 and CYFRA 21.1;
- comparing the measurement to a reference profile for the panel of biomarkers and sorting the patient into a group;
- and
- determining whether the subject is at risk for lung cancer based on the group.
Dependencies are inferred from the claim text.